116 related articles for article (PubMed ID: 20429730)
1. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
Epplen R; Stöckle M; Engelmann U; Heidenreich A; Ohlmann CH
Acta Oncol; 2011 Jan; 50(1):127-33. PubMed ID: 20429730
[TBL] [Abstract][Full Text] [Related]
2. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
4. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Fischel JL; Ciccolini J; Formento P; Ferrero JM; Milano G
Anticancer Drugs; 2006 Aug; 17(7):807-13. PubMed ID: 16926630
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line.
Freitas M; Alves V; Sarmento-Ribeiro AB; Mota-Pinto A
Biochem Biophys Res Commun; 2011 May; 408(4):713-9. PubMed ID: 21549092
[TBL] [Abstract][Full Text] [Related]
9. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
10. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
13. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
[TBL] [Abstract][Full Text] [Related]
14. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET
Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
[TBL] [Abstract][Full Text] [Related]
17. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
19. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.
Chen X; Liu Y; Wu J; Huang H; Du Z; Zhang K; Zhou D; Hung K; Goodin S; Zheng X
Cancer Genomics Proteomics; 2016; 13(2):151-60. PubMed ID: 26912805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]